You are here

DEVELOPMENT OF IMMUNO-PCR NEURODIAGNOSTIC KITS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R44NS041189-02
Agency Tracking Number: NS041189
Amount: $0.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
HEALTH PROTECTION RESEARCH, INC. 10140 BACON DR
BELTSVILLE, MD 20705
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 AREZOO CAMPBELL
 (301) 931-0811
Business Contact
Phone: (301) 931-0811
Email: HLTHPRINC@AOL.COM
Research Institution
N/A
Abstract

DESCRIPTION (adapted from applicant's abstract): Pathogenic organisms are
believed to be responsible for a number of infections, neurodegenerative and as
well as some types of neuropsychiatric diseases. Detection of neuroactive
pathogens, at the earliest stages, would be a critical factor in the diagnosis
and treatment of any possible neuropathological consequences. Enzyme-linked
immunosorbent assay (ELISA) and polymerase chain reaction (PCR) are already
being used separately as specific microbial detection methods. In the present
project, we propose to develop a technology of pathogen detection, which
combines the advantages of ELISA and those of PCR. This is expected to result
in a highly efficient, reproducible method for the detection of very small
numbers of pathogens, even before they can elicit the normal host immune
response. The project will be carried out in two phases. In phase 1, the method
of immuno-PCR will be standardized by measuring proteins and peptides that have
special importance in brain function or pathology. This will be done using
either brain cells where they are specifically and abundantly expressed, or in
heterologous cells, such as lymphocytes, where they are expressed at very low
levels, by a phenomenon known as "'illegitimate transcription". In phase 2 we
will extend the protocols developed in phase 1 to detect and quantitatively
measure some of the pathogens that are commonly found in human populations and
which are of great concern to public health authorities. Four different
approaches to immuno-PCR will be compared, based (a) on electrophoresis and
ethidium bromide staining of the amplified DNA and densitometry of the band
obtained: (b) measurement of fluorescence produced following reaction of the
PCR mixture with the dye, PicoGreen; colorimetry following reaction of
chromogenic substrate with digoxigenin-alkaline phosphate ligated to DNA; and
(d) fluorometry of the complex produced by the action of a fluorescent
substance (AttoPhos) on the DNA-digoxigenin complex.
PROPOSED COMMERCIAL APPLICATION:
(a) Development of rapid and highly sensitive, early detection kits for neuropathogens in
human and animal tissues and body fluids; (b) Evaluation of the efficiency of vaccines,
commonly used in persons at risk for infection; (c) Evaluation of the immune reaction
subsequent to primary infection or immunization, and (d) possible identification and
treatment of microorganisms responsible for idiopathic neuropathogenesis.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government